药械

订阅

MedSci主页 / 所有栏目 / 药械

DIA 2021：抗肿瘤联合用药开发策略考量

2021-05-23 CDE 周明 DIA年会

肿瘤
关注

如何从临床亟需角度出发，提高现有抗肿瘤治疗的临床获益是当下新药开发的热点。CDE 基于国内临床开发的现状，于2020年12月30日正式发布了

如何从临床亟需角度出发，提高现有抗肿瘤治疗的临床获益是当下新药开发的热点。CDE 基于国内临床开发的现状，于2020年12月30日正式发布了《抗肿瘤药联合治疗临床试验技术指导原则》从监管层面厘清生物医药行业在实际开发过程潜在误区和欠规范之处。同时CDE也借助业内专业会议平台，从多个维度分享监管部门针对国内临床开发的审评考量，特别是为了规避大量资源浪费的同质化开发，在监管层面提出“关门效应”基准。     本分享内容版权属于DIA年会讲者，CDE周明先生。   声明/Disclaimer： 上述演讲内容，仅为演讲者个人专业观点，与受聘和所属单位无关； 本演讲材料包括幻灯素材属于演讲者的个人知识产权，受所在国版权法律保护，经所有者许可方能使用。演讲者对演讲材料保留所有权力。 The above materias/slides shared during the DIA meeting are the professional viewpoints expressed by presenter, should not be attt

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639767, encodeId=7ade1639e670d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 23 17:20:35 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514304, encodeId=0c36151430463, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue May 25 05:20:35 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967955, encodeId=28ba96e9557b, content=好好学习！, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun May 23 17:06:05 CST 2021, time=2021-05-23, status=1, ipAttribution=)]
    2021-10-23 ms9608593228839890

    #DIA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1639767, encodeId=7ade1639e670d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 23 17:20:35 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514304, encodeId=0c36151430463, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue May 25 05:20:35 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967955, encodeId=28ba96e9557b, content=好好学习！, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun May 23 17:06:05 CST 2021, time=2021-05-23, status=1, ipAttribution=)]
    2021-05-25 zhouqu_8

    #联合用药#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1639767, encodeId=7ade1639e670d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Oct 23 17:20:35 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514304, encodeId=0c36151430463, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue May 25 05:20:35 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967955, encodeId=28ba96e9557b, content=好好学习！, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun May 23 17:06:05 CST 2021, time=2021-05-23, status=1, ipAttribution=)]
    2021-05-23 jyzxjiangqin

    好好学习！

    0

相关资讯

梅斯肿瘤进展速递（第005期）

编者按：梅斯医学将定期进行汇总，帮助大家概览肿瘤领域最新进展。下面是呈现给大家的最近一期的肿瘤进展。enjoy～

肿瘤医生福利：纸质书《肿瘤临床诊疗指南》0元领包邮送

动动手指，轻松薅羊毛 | 仅限前100位

“新生可达-白求恩·肿瘤患者教育”项目正式启动，为肿瘤患者保驾护航！

关爱在行动！

Nat Ecol Evol：颠覆性发现：肿瘤中心的癌细胞易扩散全身，它们遭受最恶劣的环境，也因此更强大

2021年5月17日，弗朗西斯·克里克研究所/伦敦大学学院的研究人员在 Nature 子刊 Nature Ecology & Evolution 期刊发表了题为：Selection of metast

Gastroenterology：结肠镜检查发现高风险腺瘤与无腺瘤患者相比结直肠癌的发生风险和死亡率都会增加

大肠癌（CRC）是世界上第三大最常见的恶性肿瘤，也是与癌症相关的死亡的第四大主要原因。

联拓生物合作伙伴ReViral与辉瑞公司签署收购协议，为创新疗法引入大中华区加速！

此次合作包括与ReViral签订的关于sisunatovir开发的许可协议。